CVA Family Office’s MoonLake Immunotherapeutics MLTX Stock Holding History

CVA Family Office’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.12K	Buy	+60	New	+$994	﹤0.01%	1633

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CVA Family Office's MLTX Position: Q1 2026 in Review

CVA Family Office opened a new position in MoonLake Immunotherapeutics (MLTX) in Q1 2026: 60 shares worth $1.12K. The stake represents ﹤0.01% of the portfolio and ranks #1633 among its holdings.

147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

CVA Family Office held 60 shares of MoonLake Immunotherapeutics worth $1.12K as of Q1 2026.
MoonLake Immunotherapeutics was a new CVA Family Office position in Q1 2026.
MoonLake Immunotherapeutics made up ﹤0.01% of CVA Family Office's portfolio in Q1 2026, its #1633 holding.
147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on CVA Family Office's 13F filing for Q1 2026, filed 29 Apr 2026.